Invisicare marketing deal
This article was originally published in The Rose Sheet
Executive SummarySkinvisible Pharmaceuticals and Merck affiliate EMD Chemicals' cosmetics unit announce "exclusive worldwide sales, collaboration and distribution agreement for the personal care market involving Skinvisible's patented polymer-based topical delivery vehicle, Invisicare." Under the agreement, EMD will market the technology, which "is specially formulated to carry water insoluble active ingredients in water-based systems without the use of alcohol, silicones, petrolatum or other organic solvents," according to Skinvisible. Firm is giving EMD future rights to acquire an equity interest in Skinvisible...
You may also be interested in...
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.
Tech Companies Grappling With A Brave New World Of Regulations While Developing Digital-Health Products
Software firms interested in the digital-health arena are engaging US FDA more and bolstering their regulatory credentials to navigate an unfamiliar regulatory landscape, industry experts tell Medtech Insight.
Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.